INTERVAL

In over 100 years of blood donation practice, INTERVAL is the first randomised controlled trial to assess the impact of varying the frequency of blood donation on donor health and the blood supply. It provided policy-makers with evidence that collecting blood more frequently than current intervals can be implemented over two years without impacting on donor health, allowing better management of the supply to the NHS of units of blood with in-demand blood groups. INTERVAL was designed to deliver a multi-purpose strategy: an initial purpose related to blood donation research aiming to improve NHS Blood and Transplant’s core services and a longer-term purpose related to the creation of a comprehensive resource that will enable detailed studies of health-related questions.

Approximately 50,000 generally healthy blood donors were recruited between June 2012 and June 2014 from 25 NHS Blood Donation centres across England. Approximately equal numbers of men and women; aged from 18-80; ~93% white ancestry. All participants completed brief online questionnaires at baseline and gave blood samples for research purposes. Participants were randomised to giving blood every 8/10/12 weeks (for men) and 12/14/16 weeks (for women) over a 2-year period. ~30,000 participants returned after 2 years and completed a brief online questionnaire and gave further blood samples for research purposes.

The baseline questionnaire includes brief lifestyle information (smoking, alcohol consumption, etc), iron-related questions (e.g., red meat consumption), self-reported height and weight, etc. The SF-36 questionnaire was completed online at baseline and 2-years, with a 6-monthly SF-12 questionnaire between baseline and 2-years.

All participants have had the Affymetrix Axiom UK Biobank genotyping array assayed and then imputed to 1000G+UK10K combined reference panel (80M variants in total). 4,000 participants have 50X whole-exome sequencing and 12,000 participants have 15X whole-genome sequencing. Whole-blood RNA sequencing has commenced in ~5,000 participants.

The dataset also contains data on clinical chemistry biomarkers, blood cell traits, >200 lipoproteins, metabolomics (Metabolon HD4), lipidomics, and proteomics (SomaLogic, Olink), either cohort-wide or is large sub-sets of the cohort.